Efficacy and Safety of Simultaneous Initiation of SGLT2 Inhibitors and Mineralocorticoid Receptor Antagonists in Patients With Chronic Kidney Disease or Heart Failure

Key Points

• To evaluate the efficacy and safety of starting SGLT2 inhibitors alongside mineralocorticoid receptor antagonists in patients with chronic kidney disease or heart failure.
• Randomized trial design involving patients with chronic kidney disease or heart failure.
• Simultaneous initiation of SGLT2 inhibitors and mineralocorticoid receptor antagonists.
• Assessment of efficacy and safety outcomes.
• Significant improvement observed in kidney function; specific data on event rates available in full results.
• Reduced hospitalization rates for heart failure noted in patients receiving both treatments.
• No serious safety concerns reported related to the combined use of medications.